메뉴 건너뛰기




Volumn 8, Issue , 2014, Pages 1563-1575

Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development

Author keywords

Biopharmaceutics classification system; In silico; Intestinal permeability; Partition coefficient; Solubility

Indexed keywords

ARTICLE; BIOPHARMACEUTICS CLASSIFICATION SYSTEM; COMPUTER ANALYSIS; COMPUTER MODEL; COMPUTER PREDICTION; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; DRUG CLASSIFICATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STRUCTURE; HUMAN; HUMAN TISSUE; MELTING POINT; ORAL DRUG ADMINISTRATION; PHYSICAL CHEMISTRY; PRODUCT DEVELOPMENT; REFERENCE VALUE; THERMODYNAMICS; ALGORITHM; COMPUTER PROGRAM; COMPUTER SIMULATION; DRUG DEVELOPMENT; PERMEABILITY; PHARMACEUTICS; SOLUBILITY;

EID: 84908073820     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S68909     Document Type: Article
Times cited : (46)

References (80)
  • 1
    • 84862025527 scopus 로고    scopus 로고
    • The fraction dose absorbed, in humans, and high jejunal human permeability relationship
    • Dahan A, Lennernäs H, Amidon GL. The fraction dose absorbed, in humans, and high jejunal human permeability relationship. Mol Pharm. 2012;9(6):1847-1851.
    • (2012) Mol Pharm. , vol.9 , Issue.6 , pp. 1847-1851
    • Dahan, A.1    Lennernäs, H.2    Amidon, G.L.3
  • 2
    • 14744272833 scopus 로고    scopus 로고
    • The use of biopharmaceutic classification of drugs in drug discovery and development: Current status and future extension
    • Lennernäs H, Abrahamsson B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol. 2005;57(3):273-285.
    • (2005) J Pharm Pharmacol. , vol.57 , Issue.3 , pp. 273-285
    • Lennernäs, H.1    Abrahamsson, B.2
  • 3
    • 0028948839 scopus 로고
    • A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability
    • Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3): 413-420.
    • (1995) Pharm Res. , vol.12 , Issue.3 , pp. 413-420
    • Amidon, G.L.1    Lennernäs, H.2    Shah, V.P.3    Crison, J.R.4
  • 4
    • 80052037863 scopus 로고    scopus 로고
    • Bioequivalence of oral products and the biopharmaceutics classification system: Science, regulation, and public policy
    • Amidon KS, Langguth P, Lennernäs H, Yu LX, Amidon GL. Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy. Clin Pharmacol Ther. 2011; 90(3):467-470.
    • (2011) Clin Pharmacol Ther. , vol.90 , Issue.3 , pp. 467-470
    • Amidon, K.S.1    Langguth, P.2    Lennernäs, H.3    Yu, L.X.4    Amidon, G.L.5
  • 5
    • 72949123710 scopus 로고    scopus 로고
    • Prediction of solubility and permeability class membership: Provisional BCS classification of the world's top oral drugs
    • Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J. 2009;11(4):740-746.
    • (2009) AAPS J. , vol.11 , Issue.4 , pp. 740-746
    • Dahan, A.1    Miller, J.M.2    Amidon, G.L.3
  • 6
    • 0343527392 scopus 로고    scopus 로고
    • Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards
    • Löbenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm. 2000; 50(1):3-12.
    • (2000) Eur J Pharm Biopharm. , vol.50 , Issue.1 , pp. 3-12
    • Löbenberg, R.1    Amidon, G.L.2
  • 7
    • 0036000312 scopus 로고    scopus 로고
    • A mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals
    • Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol. 2002;42(6):620-643.
    • (2002) J Clin Pharmacol. , vol.42 , Issue.6 , pp. 620-643
    • Martinez, M.N.1    Amidon, G.L.2
  • 9
    • 0035997323 scopus 로고    scopus 로고
    • Biopharmaceutics classification system: The scientific basis for biowaiver extensions
    • Yu LX, Amidon G, Polli J, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res. 2002; 19(7):921-925.
    • (2002) Pharm Res. , vol.19 , Issue.7 , pp. 921-925
    • Yu, L.X.1    Amidon, G.2    Polli, J.3
  • 10
    • 53849122291 scopus 로고    scopus 로고
    • Application of the biopharmaceutical classification system in clinical drug development-an industrial view
    • Cook J, Addicks W, Wu Y. Application of the biopharmaceutical classification system in clinical drug development-an industrial view. AAPS J. 2008;10(2):306-310.
    • (2008) AAPS J. , vol.10 , Issue.2 , pp. 306-310
    • Cook, J.1    Addicks, W.2    Wu, Y.3
  • 11
    • 51249095402 scopus 로고    scopus 로고
    • Use of the biopharmaceutical classification system in early drug development
    • Ku MS. Use of the biopharmaceutical classification system in early drug development. AAPS J. 2008;10(1):208-212.
    • (2008) AAPS J. , vol.10 , Issue.1 , pp. 208-212
    • Ku, M.S.1
  • 12
    • 84878660708 scopus 로고    scopus 로고
    • Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number
    • Pham-The H, Garrigues T, Bermejo M, González-Álvarez I, Monteagudo MC, Cabrera-Pérez MÁ. Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number. Mol Pharm. 2013;10(6):2445-2461.
    • (2013) Mol Pharm. , vol.10 , Issue.6 , pp. 2445-2461
    • Pham-The, H.1    Garrigues, T.2    Bermejo, M.3    González-Álvarez, I.4    Monteagudo, M.C.5    Cabrera-Pérez, M.Á.6
  • 13
    • 84887346931 scopus 로고    scopus 로고
    • Purely in silico BCS classification: Science based quality standards for the world's drugs
    • Dahan A, Wolk O, Kim YH, et al. Purely in silico BCS classification: science based quality standards for the world's drugs. Mol Pharm. 2013; 10(11):4378-4390.
    • (2013) Mol Pharm. , vol.10 , Issue.11 , pp. 4378-4390
    • Dahan, A.1    Wolk, O.2    Kim, Y.H.3
  • 14
    • 84899666320 scopus 로고    scopus 로고
    • Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo
    • Lennernäs H, Aarons L, Augustijns P, et al. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo. Eur J Pharm Sci. 2014;16(57):292-299.
    • (2014) Eur J Pharm Sci. , vol.16 , Issue.57 , pp. 292-299
    • Lennernäs, H.1    Aarons, L.2    Augustijns, P.3
  • 15
    • 84877070455 scopus 로고    scopus 로고
    • Regional-dependent intestinal permeability and BCS classification: Elucidation of pH-related complexity in rats using pseudoephedrine
    • Fairstein M, Swissa R, Dahan A. Regional-dependent intestinal permeability and BCS classification: elucidation of pH-related complexity in rats using pseudoephedrine. AAPS J. 2013;15(2):589-597.
    • (2013) AAPS J. , vol.15 , Issue.2 , pp. 589-597
    • Fairstein, M.1    Swissa, R.2    Dahan, A.3
  • 16
    • 84863301279 scopus 로고    scopus 로고
    • A win-win solution in oral delivery of lipophilic drugs: Supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability
    • Miller JM, Beig A, Carr RA, Spence JK, Dahan A. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability. Mol Pharm. 2012;9(7):2009-2016.
    • (2012) Mol Pharm. , vol.9 , Issue.7 , pp. 2009-2016
    • Miller, J.M.1    Beig, A.2    Carr, R.A.3    Spence, J.K.4    Dahan, A.5
  • 17
    • 84863229573 scopus 로고    scopus 로고
    • The solubility-permeability interplay when using cosolvents for solubilization: Revising the way we use solubility-enabling formulations
    • Miller JM, Beig A, Carr RA, Webster GK, Dahan A. The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations. Mol Pharm. 2012;9(3): 581-590.
    • (2012) Mol Pharm. , vol.9 , Issue.3 , pp. 581-590
    • Miller, J.M.1    Beig, A.2    Carr, R.A.3    Webster, G.K.4    Dahan, A.5
  • 18
    • 84860702965 scopus 로고    scopus 로고
    • Predicting the solubility-permeability interplay when using cyclodextrins in solubility-enabling formulations: Model validation
    • Miller JM, Dahan A. Predicting the solubility-permeability interplay when using cyclodextrins in solubility-enabling formulations: model validation. Int J Pharm. 2012;430(1-2):388-391.
    • (2012) Int J Pharm. , vol.430 , Issue.1-2 , pp. 388-391
    • Miller, J.M.1    Dahan, A.2
  • 19
    • 0031925268 scopus 로고    scopus 로고
    • Human intestinal permeability
    • Lennernäs H. Human intestinal permeability. J Pharm Sci. 1998;87(4): 403-410.
    • (1998) J Pharm Sci. , vol.87 , Issue.4 , pp. 403-410
    • Lennernäs, H.1
  • 20
    • 84899643093 scopus 로고    scopus 로고
    • Regional intestinal drug permeation: Biopharmaceutics and drug development
    • Lennernäs H. Regional intestinal drug permeation: biopharmaceutics and drug development. Eur J Pharm Sci. 2014;16(57):333-341.
    • (2014) Eur J Pharm Sci. , vol.16 , Issue.57 , pp. 333-341
    • Lennernäs, H.1
  • 21
    • 84891767016 scopus 로고    scopus 로고
    • Human in vivo regional intestinal permeability: Importance for pharmaceutical drug development
    • Lennernäs H. Human in vivo regional intestinal permeability: importance for pharmaceutical drug development. Mol Pharm. 2014;11(1):12-23.
    • (2014) Mol Pharm. , vol.11 , Issue.1 , pp. 12-23
    • Lennernäs, H.1
  • 22
    • 74149085130 scopus 로고    scopus 로고
    • MRP2 mediated drug-drug interaction: Indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting
    • Dahan A, Amidon GL. MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. Int J Pharm. 2010;386(1-2):216-220.
    • (2010) Int J Pharm. , vol.386 , Issue.1-2 , pp. 216-220
    • Dahan, A.1    Amidon, G.L.2
  • 23
    • 68049095727 scopus 로고    scopus 로고
    • The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: Characterization of its intestinal epithelial cell efflux transport
    • Dahan A, Sabit H, Amidon GL. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009;11(2):205-213.
    • (2009) AAPS J. , vol.11 , Issue.2 , pp. 205-213
    • Dahan, A.1    Sabit, H.2    Amidon, G.L.3
  • 24
    • 70349414560 scopus 로고    scopus 로고
    • Multiple efflux pumps are involved in the transepithelial transport of colchicine: Combined effect of P-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine
    • Dahan A, Sabit H, Amidon GL. Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of P-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab Dispos. 2009;37(10):2028-2036.
    • (2009) Drug Metab Dispos. , vol.37 , Issue.10 , pp. 2028-2036
    • Dahan, A.1    Sabit, H.2    Amidon, G.L.3
  • 25
    • 77955235031 scopus 로고    scopus 로고
    • Enabling the intestinal absorption of highly polar antiviral agents: Ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir
    • Miller JM, Dahan A, Gupta D, Varghese S, Amidon GL. Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir. Mol Pharm. 2010;7(4):1223-1234.
    • (2010) Mol Pharm. , vol.7 , Issue.4 , pp. 1223-1234
    • Miller, J.M.1    Dahan, A.2    Gupta, D.3    Varghese, S.4    Amidon, G.L.5
  • 26
    • 0034461768 scopus 로고    scopus 로고
    • Drug-like properties and the causes of poor solubility and poor permeability
    • Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(1): 235-249.
    • (2000) J Pharmacol Toxicol Methods. , vol.44 , Issue.1 , pp. 235-249
    • Lipinski, C.A.1
  • 27
    • 0035289779 scopus 로고    scopus 로고
    • Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
    • Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46(1-3):3-26.
    • (2001) Adv Drug Deliv Rev. , vol.46 , Issue.1-3 , pp. 3-26
    • Lipinski, C.A.1    Lombardo, F.2    Dominy, B.W.3    Feeney, P.J.4
  • 29
    • 83555174958 scopus 로고    scopus 로고
    • BDDCS applied to over 900 drugs
    • Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J. 2011;13(4):519-547.
    • (2011) AAPS J. , vol.13 , Issue.4 , pp. 519-547
    • Benet, L.Z.1    Broccatelli, F.2    Oprea, T.I.3
  • 31
    • 24544469216 scopus 로고
    • Calculating log Poct from structures
    • Leo AJ. Calculating log Poct from structures. Chemical Reviews. 1993; 93(4):1281-1306.
    • (1993) Chemical Reviews. , vol.93 , Issue.4 , pp. 1281-1306
    • Leo, A.J.1
  • 33
    • 0023289451 scopus 로고
    • Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactions
    • Ghose AK, Crippen GM. Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactions. J Chem Inf Comput Sci. 1987;27(1):21-35.
    • (1987) J Chem Inf Comput Sci. , vol.27 , Issue.1 , pp. 21-35
    • Ghose, A.K.1    Crippen, G.M.2
  • 34
    • 0001509942 scopus 로고    scopus 로고
    • Prediction of physicochemical parameters by atomic contributions
    • Wildman SA, Crippen GM. Prediction of physicochemical parameters by atomic contributions. J Chem Inf Comput Sci. 1999;39(5):868-873.
    • (1999) J Chem Inf Comput Sci. , vol.39 , Issue.5 , pp. 868-873
    • Wildman, S.A.1    Crippen, G.M.2
  • 35
    • 35649009910 scopus 로고    scopus 로고
    • Intestinal permeability and its relevance for absorption and elimination
    • Lennernäs H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica. 2007;37(10-11):1015-1051.
    • (2007) Xenobiotica. , vol.37 , Issue.10-11 , pp. 1015-1051
    • Lennernäs, H.1
  • 36
    • 77957729688 scopus 로고    scopus 로고
    • High-permeability criterion for BCS classification: Segmental/pH dependent permeability considerations
    • Dahan A, Miller JM, Hilfinger JM, et al. High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. Mol Pharm. 2010;7(5):1827-1834.
    • (2010) Mol Pharm. , vol.7 , Issue.5 , pp. 1827-1834
    • Dahan, A.1    Miller, J.M.2    Hilfinger, J.M.3
  • 38
    • 84899843284 scopus 로고    scopus 로고
    • The low/high BCS permeability class boundary: Physicochemical comparison of metoprolol and labetalol
    • Zur M, Gasparini M, Wolk O, Amidon GL, Dahan A. The low/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol. Mol Pharm. 2014;11(5):1707-1714.
    • (2014) Mol Pharm. , vol.11 , Issue.5 , pp. 1707-1714
    • Zur, M.1    Gasparini, M.2    Wolk, O.3    Amidon, G.L.4    Dahan, A.5
  • 41
    • 34247236764 scopus 로고    scopus 로고
    • Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein
    • Chu XY, Bleasby K, Yabut J, et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther. 2007;321(2):673-683.
    • (2007) J Pharmacol Exp Ther. , vol.321 , Issue.2 , pp. 673-683
    • Chu, X.Y.1    Bleasby, K.2    Yabut, J.3
  • 42
    • 0028826927 scopus 로고
    • Differential recognition of beta-lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2
    • Ganapathy ME, Brandsch M, Prasad PD, Ganapathy V, Leibach FH. Differential recognition of beta-lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J Biol Chem. 1995; 270(43):25672-25677.
    • (1995) J Biol Chem. , vol.270 , Issue.43 , pp. 25672-25677
    • Ganapathy, M.E.1    Brandsch, M.2    Prasad, P.D.3    Ganapathy, V.4    Leibach, F.H.5
  • 43
    • 0344572686 scopus 로고    scopus 로고
    • CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs
    • Han HK, Rhie JK, Oh DM, et al. CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci. 1999;88(3):347-350.
    • (1999) J Pharm Sci. , vol.88 , Issue.3 , pp. 347-350
    • Han, H.K.1    Rhie, J.K.2    Oh, D.M.3
  • 44
    • 0037303497 scopus 로고    scopus 로고
    • Functional properties of multispecific amino acid transporters and their implications to transporter-mediated toxicity
    • Kanai Y, Endou H. Functional properties of multispecific amino acid transporters and their implications to transporter-mediated toxicity. J Toxicol Sci. 2003;28(1):1-17.
    • (2003) J Toxicol Sci. , vol.28 , Issue.1 , pp. 1-17
    • Kanai, Y.1    Endou, H.2
  • 45
    • 0025966310 scopus 로고
    • Oral absorption of peptides: Influence of pH and inhibitors on the intestinal hydrolysis of leu-enkephalin and analogues
    • Friedman DI, Amidon GL. Oral absorption of peptides: influence of pH and inhibitors on the intestinal hydrolysis of leu-enkephalin and analogues. Pharm Res. 1991;8(1):93-96.
    • (1991) Pharm Res. , vol.8 , Issue.1 , pp. 93-96
    • Friedman, D.I.1    Amidon, G.L.2
  • 46
    • 0019987023 scopus 로고
    • Intestinal absorption of amino acid derivatives: Importance of the free alpha-amino group
    • Amidon GL, Chang M, Fleisher D, Allen R. Intestinal absorption of amino acid derivatives: importance of the free alpha-amino group. J Pharm Sci. 1982;71(10):1138-1141.
    • (1982) J Pharm Sci. , vol.71 , Issue.10 , pp. 1138-1141
    • Amidon, G.L.1    Chang, M.2    Fleisher, D.3    Allen, R.4
  • 47
    • 84864273540 scopus 로고    scopus 로고
    • Targeted prodrugs in oral drug delivery: The modern molecular biopharmaceutical approach
    • Dahan A, Khamis M, Agbaria R, Karaman R. Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach. Expert Opin Drug Deliv. 2012;9(8):1001-1013.
    • (2012) Expert Opin Drug Deliv. , vol.9 , Issue.8 , pp. 1001-1013
    • Dahan, A.1    Khamis, M.2    Agbaria, R.3    Karaman, R.4
  • 48
    • 84884694215 scopus 로고    scopus 로고
    • Impact of peptide transporter 1 on the intestinal absorption and pharmacokinetics of valacyclovir after oral dose escalation in wild-type and PepT1 knockout mice
    • Yang, B, Hu Y, Smith DE. Impact of peptide transporter 1 on the intestinal absorption and pharmacokinetics of valacyclovir after oral dose escalation in wild-type and PepT1 knockout mice. Drug Metab Dispos. 2013;41(10):1867-1874.
    • (2013) Drug Metab Dispos. , vol.41 , Issue.10 , pp. 1867-1874
    • Yang, B.1    Hu, Y.2    Smith, D.E.3
  • 49
    • 84874045942 scopus 로고    scopus 로고
    • Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice
    • Yang B, Smith DE. Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice. Drug Metab Dispos. 2013;41(3):608-614.
    • (2013) Drug Metab Dispos. , vol.41 , Issue.3 , pp. 608-614
    • Yang, B.1    Smith, D.E.2
  • 50
    • 0034061961 scopus 로고    scopus 로고
    • Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers
    • Soldner A, Benet LZ, Mutschler E, Christians U. Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol. 2000;129(6):1235-1243.
    • (2000) Br J Pharmacol. , vol.129 , Issue.6 , pp. 1235-1243
    • Soldner, A.1    Benet, L.Z.2    Mutschler, E.3    Christians, U.4
  • 51
    • 77951031222 scopus 로고    scopus 로고
    • Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters
    • Weiss J, Sauer A, Divac N, et al. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010;31(2-3):150-161.
    • (2010) Biopharm Drug Dispos. , vol.31 , Issue.2-3 , pp. 150-161
    • Weiss, J.1    Sauer, A.2    Divac, N.3
  • 53
    • 84874608792 scopus 로고    scopus 로고
    • Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: Use as a reference standard for BCS classification
    • Incecayir T, Tsume Y, Amidon GL. Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification. Mol Pharm. 2013;10(3): 958-966.
    • (2013) Mol Pharm. , vol.10 , Issue.3 , pp. 958-966
    • Incecayir, T.1    Tsume, Y.2    Amidon, G.L.3
  • 54
    • 3242728351 scopus 로고    scopus 로고
    • Molecular properties of WHO essential drugs and provisional biopharmaceutical classification
    • Kasim NA, Whitehouse M, Ramachandran C, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm. 2004;1(1):85-96.
    • (2004) Mol Pharm. , vol.1 , Issue.1 , pp. 85-96
    • Kasim, N.A.1    Whitehouse, M.2    Ramachandran, C.3
  • 55
    • 33846176619 scopus 로고    scopus 로고
    • A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan
    • Takagi T, Ramachandran C, Bermejo M, Yamashita S, Yu LX, Amidon GL. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm. 2006;3(6):631-643.
    • (2006) Mol Pharm. , vol.3 , Issue.6 , pp. 631-643
    • Takagi, T.1    Ramachandran, C.2    Bermejo, M.3    Yamashita, S.4    Yu, L.X.5    Amidon, G.L.6
  • 56
    • 0041698448 scopus 로고    scopus 로고
    • Molecular descriptors influencing melting point and their role in classification of solid drugs
    • Bergström CAS, Norinder U, Luthman K, Artursson P. Molecular descriptors influencing melting point and their role in classification of solid drugs. J Chem Inf Comput Sci. 2003;43(4):1177-1185.
    • (2003) J Chem Inf Comput Sci. , vol.43 , Issue.4 , pp. 1177-1185
    • Bergström, C.A.S.1    Norinder, U.2    Luthman, K.3    Artursson, P.4
  • 57
    • 77956075075 scopus 로고    scopus 로고
    • In silico prediction of the melting points of ionic liquids from thermodynamic considerations: A case study on 67 salts with a melting point range of 337 degrees C
    • Preiss U, Bulut S, Krossing I. In silico prediction of the melting points of ionic liquids from thermodynamic considerations: a case study on 67 salts with a melting point range of 337 degrees C. J Phys Chem B. 2010;114(34):11133-11140.
    • (2010) J Phys Chem B. , vol.114 , Issue.34 , pp. 11133-11140
    • Preiss, U.1    Bulut, S.2    Krossing, I.3
  • 58
    • 84859962992 scopus 로고    scopus 로고
    • A comparison of methods for melting point calculation using molecular dynamics simulations
    • Zhang Y, Maginn EJ. A comparison of methods for melting point calculation using molecular dynamics simulations. J Chem Phys. 2012; 136(14):144116.
    • (2012) J Chem Phys. , vol.136 , Issue.14
    • Zhang, Y.1    Maginn, E.J.2
  • 59
    • 17644380257 scopus 로고    scopus 로고
    • Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system
    • Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22(1):11-23.
    • (2005) Pharm Res. , vol.22 , Issue.1 , pp. 11-23
    • Wu, C.Y.1    Benet, L.Z.2
  • 60
    • 39149115065 scopus 로고    scopus 로고
    • Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption
    • Custodio JM, Wu CY, Benet LZ. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008;60(6):717-733.
    • (2008) Adv Drug Deliv Rev. , vol.60 , Issue.6 , pp. 717-733
    • Custodio, J.M.1    Wu, C.Y.2    Benet, L.Z.3
  • 61
    • 84870665478 scopus 로고    scopus 로고
    • The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development
    • Benet LZ. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J Pharm Sci. 2013;102(1):34-42.
    • (2013) J Pharm Sci. , vol.102 , Issue.1 , pp. 34-42
    • Benet, L.Z.1
  • 62
    • 84877077844 scopus 로고    scopus 로고
    • The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: Increased apparent solubility and drug flux through the intestinal membrane
    • Dahan A, Beig A, Ioffe-Dahan V, Agbaria R, Miller J. The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane. AAPS J. 2013;15(2):347-353.
    • (2013) AAPS J. , vol.15 , Issue.2 , pp. 347-353
    • Dahan, A.1    Beig, A.2    Ioffe-Dahan, V.3    Agbaria, R.4    Miller, J.5
  • 63
    • 84858039015 scopus 로고    scopus 로고
    • The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs
    • Dahan A, Miller JM. The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs. AAPS J. 2012;14(2):244-251.
    • (2012) AAPS J. , vol.14 , Issue.2 , pp. 244-251
    • Dahan, A.1    Miller, J.M.2
  • 64
    • 84860876423 scopus 로고    scopus 로고
    • Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug
    • Morgen M, Bloom C, Beyerinck R, et al. Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug. Pharm Res. 2012; 29(2):427-440.
    • (2012) Pharm Res. , vol.29 , Issue.2 , pp. 427-440
    • Morgen, M.1    Bloom, C.2    Beyerinck, R.3
  • 65
    • 84861593280 scopus 로고    scopus 로고
    • Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: The effect of PEG-400 on carbamazepine absorption
    • Beig A, Miller JM, Dahan A. Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption. Eur J Pharm Biopharm. 2012;81(2):386-391.
    • (2012) Eur J Pharm Biopharm. , vol.81 , Issue.2 , pp. 386-391
    • Beig, A.1    Miller, J.M.2    Dahan, A.3
  • 66
    • 80053535563 scopus 로고    scopus 로고
    • The solubility-permeability interplay: Mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation
    • Miller JM, Beig A, Krieg BJ, et al. The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation. Mol Pharm. 2011;8(5): 1848-1856.
    • (2011) Mol Pharm. , vol.8 , Issue.5 , pp. 1848-1856
    • Miller, J.M.1    Beig, A.2    Krieg, B.J.3
  • 67
    • 33750592309 scopus 로고    scopus 로고
    • Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: Correlation with in vivo data and the relationship to intra-enterocyte processes in rats
    • Dahan A, Hoffman A. Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: Correlation with in vivo data and the relationship to intra-enterocyte processes in rats. Pharm Res. 2006;23(9):2165-2174.
    • (2006) Pharm Res. , vol.23 , Issue.9 , pp. 2165-2174
    • Dahan, A.1    Hoffman, A.2
  • 68
    • 34250867442 scopus 로고    scopus 로고
    • The effect of different lipid based formulations on the oral absorption of lipophilic drugs: The ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats
    • Dahan A, Hoffman A. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. Eur J Pharm Biopharm. 2007;67(1):96-105.
    • (2007) Eur J Pharm Biopharm. , vol.67 , Issue.1 , pp. 96-105
    • Dahan, A.1    Hoffman, A.2
  • 69
    • 44649133855 scopus 로고    scopus 로고
    • Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs
    • Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release. 2008;129(1):1-10.
    • (2008) J Control Release. , vol.129 , Issue.1 , pp. 1-10
    • Dahan, A.1    Hoffman, A.2
  • 70
    • 75449099531 scopus 로고    scopus 로고
    • Nano-sized water-in-oil-in-water emulsion enhances intestinal absorption of calcein, a high solubility and low permeability compound
    • Koga K, Takarada N, Takada K. Nano-sized water-in-oil-in-water emulsion enhances intestinal absorption of calcein, a high solubility and low permeability compound. Eur J Pharm Biopharm. 2010;74(2): 223-232.
    • (2010) Eur J Pharm Biopharm. , vol.74 , Issue.2 , pp. 223-232
    • Koga, K.1    Takarada, N.2    Takada, K.3
  • 71
    • 84880483077 scopus 로고    scopus 로고
    • Oral delivery of lipophilic drugs: The tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations
    • Beig A, Agbaria R, Dahan A. Oral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations. PLoS One. 2013;8(7):e68237.
    • (2013) PLoS One. , vol.8 , Issue.7
    • Beig, A.1    Agbaria, R.2    Dahan, A.3
  • 72
    • 84889097231 scopus 로고    scopus 로고
    • The interaction of nifedipine with selected cyclodextrins and the subsequent solubility-permeability trade-off
    • Beig A, Miller JM, Dahan A. The interaction of nifedipine with selected cyclodextrins and the subsequent solubility-permeability trade-off. Eur J Pharm Biopharm. 2013;85(3):1293-1299.
    • (2013) Eur J Pharm Biopharm. , vol.85 , Issue.3 , pp. 1293-1299
    • Beig, A.1    Miller, J.M.2    Dahan, A.3
  • 73
    • 77951590174 scopus 로고    scopus 로고
    • The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: Mechanistic modeling and application to progesterone
    • Dahan A, Miller JM, Hoffman A, Amidon GE, Amidon GL. The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone. J Pharm Sci. 2010;99(6):2739-2749.
    • (2010) J Pharm Sci. , vol.99 , Issue.6 , pp. 2739-2749
    • Dahan, A.1    Miller, J.M.2    Hoffman, A.3    Amidon, G.E.4    Amidon, G.L.5
  • 74
    • 67349130543 scopus 로고    scopus 로고
    • Quasi-equilibrium analysis of the ion-pair mediated membrane transport of low-permeability drugs
    • Miller JM, Dahan A, Gupta D, Varghese S, Amidon GL. Quasi-equilibrium analysis of the ion-pair mediated membrane transport of low-permeability drugs. J Control Release. 2009;137(1):31-37.
    • (2009) J Control Release. , vol.137 , Issue.1 , pp. 31-37
    • Miller, J.M.1    Dahan, A.2    Gupta, D.3    Varghese, S.4    Amidon, G.L.5
  • 75
    • 27744605985 scopus 로고    scopus 로고
    • In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies
    • Sharma P, Varma MV, Chawla HP, Panchagnula R. In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies. Farmaco. 2005;60(11-12):874-883.
    • (2005) Farmaco. , vol.60 , Issue.11-12 , pp. 874-883
    • Sharma, P.1    Varma, M.V.2    Chawla, H.P.3    Panchagnula, R.4
  • 76
    • 77249109864 scopus 로고    scopus 로고
    • Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: A double-targeted prodrug approach
    • Sun J, Dahan A, Amidon GL. Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach. J Med Chem. 2010;53(2):624-632.
    • (2010) J Med Chem. , vol.53 , Issue.2 , pp. 624-632
    • Sun, J.1    Dahan, A.2    Amidon, G.L.3
  • 77
    • 84873325984 scopus 로고    scopus 로고
    • Increasing oral absorption of polar neuraminidase inhibitors: A prodrug transporter approach applied to oseltamivir analogue
    • Gupta D, Varghese Gupta S, Dahan A, et al. Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue. Mol Pharm. 2013;10(2):512-522.
    • (2013) Mol Pharm. , vol.10 , Issue.2 , pp. 512-522
    • Gupta, D.1    Varghese Gupta, S.2    Dahan, A.3
  • 78
    • 82955173045 scopus 로고    scopus 로고
    • Enhancing the intestinal membrane permeability of zanamivir: A carrier mediated prodrug approach
    • Varghese Gupta S, Gupta D, Sun J, et al. Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach. Mol Pharm. 2011;8(6):2358-2367.
    • (2011) Mol Pharm. , vol.8 , Issue.6 , pp. 2358-2367
    • Varghese Gupta, S.1    Gupta, D.2    Sun, J.3
  • 79
    • 84867101894 scopus 로고    scopus 로고
    • Mechanistic investigation of food effect on disintegration and dissolution of BCS class III compound solid formulations: The importance of viscosity
    • Radwan A, Amidon GL, Langguth P. Mechanistic investigation of food effect on disintegration and dissolution of BCS class III compound solid formulations: the importance of viscosity. Biopharm Drug Dispos. 2012; 33(7):403-416.
    • (2012) Biopharm Drug Dispos. , vol.33 , Issue.7 , pp. 403-416
    • Radwan, A.1    Amidon, G.L.2    Langguth, P.3
  • 80
    • 38549101558 scopus 로고    scopus 로고
    • The oral absorption of phospholipid prodrugs: In vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration
    • Dahan A, Duvdevani R, Shapiro I, Elmann A, Finkelstein E, Hoffman A. The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration. J Control Release. 2008; 126(1):1-9.
    • (2008) J Control Release. , vol.126 , Issue.1 , pp. 1-9
    • Dahan, A.1    Duvdevani, R.2    Shapiro, I.3    Elmann, A.4    Finkelstein, E.5    Hoffman, A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.